Breast cancer medication declared safe for use

22 June 2012

A drug to treat people suffering from late stage breast cancer has received approval from the US Food and Drug Administration, paving the way for a global roll-out.

The FDA declared that Perjeta (pertuzumab), which is made by Genentech, is effective and safe for use in breast cancer sufferers.

According to the manufacturers, the medication works by significantly delaying the onset of the worst stage of breast cancer and can provide sufferers with extended quality of life.

Case studies into the efficacy of the drug involving 808 women found that just 69 of 402 given Perjeta in addition to Herceptin and chemotherapy died, compared with 96 of 406 women given Herceptin and chemotherapy alone.

Dr Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, commented: "Given the need for additional treatments for metastatic breast cancer, we made the decision to approve this drug today and not to delay its availability to patients pending resolution of the production issues relating to future supply."

Posted by Jeanette Royston

Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:

or

Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.

or

Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...

Categories

Cancer

© Spire Healthcare Group plc (2016)